[go: up one dir, main page]

BG104119A - A new composition - Google Patents

A new composition

Info

Publication number
BG104119A
BG104119A BG104119A BG10411900A BG104119A BG 104119 A BG104119 A BG 104119A BG 104119 A BG104119 A BG 104119A BG 10411900 A BG10411900 A BG 10411900A BG 104119 A BG104119 A BG 104119A
Authority
BG
Bulgaria
Prior art keywords
new composition
betablocker
reversive
serotonin
pharmaceutical composition
Prior art date
Application number
BG104119A
Other languages
Bulgarian (bg)
Inventor
Paul CUMMINGS
Ian TULLOCH
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104119A publication Critical patent/BG104119A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a pharmaceutical composition including SSRI (Serotonin Reversive Assimilation Inhibitor) in a form with rapid release and a betablocker in a form with delayed release. 13 claims
BG104119A 1997-07-11 2000-02-01 A new composition BG104119A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9714675.7A GB9714675D0 (en) 1997-07-11 1997-07-11 Novel composition
PCT/EP1998/004971 WO1999002142A2 (en) 1997-07-11 1998-07-07 Novel composition comprising an ssri and a beta-blocker

Publications (1)

Publication Number Publication Date
BG104119A true BG104119A (en) 2000-12-29

Family

ID=10815744

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104119A BG104119A (en) 1997-07-11 2000-02-01 A new composition

Country Status (26)

Country Link
EP (1) EP0996466A2 (en)
JP (1) JP2002508003A (en)
KR (1) KR20010021644A (en)
CN (1) CN1262627A (en)
AP (1) AP2000001728A0 (en)
AR (1) AR016128A1 (en)
AU (1) AU9340198A (en)
BG (1) BG104119A (en)
BR (1) BR9810996A (en)
CA (1) CA2295822A1 (en)
CO (1) CO4950552A1 (en)
DZ (1) DZ2556A1 (en)
EA (1) EA200000112A1 (en)
GB (1) GB9714675D0 (en)
HU (1) HUP0003074A3 (en)
ID (1) ID24191A (en)
IL (1) IL133869A0 (en)
MA (1) MA24604A1 (en)
NO (1) NO20000107D0 (en)
OA (1) OA11276A (en)
PE (1) PE99699A1 (en)
PL (1) PL338017A1 (en)
SK (1) SK72000A3 (en)
TR (1) TR200000074T2 (en)
WO (1) WO1999002142A2 (en)
ZA (1) ZA986138B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1121111B1 (en) 1998-10-15 2010-02-10 Imperial Innovations Limited Compounds for the treatment of weight loss
EP2020229A1 (en) 1998-11-02 2009-02-04 Elan Pharma International Limited Multiparticulate modified release composition
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CN102716101A (en) 1999-10-29 2012-10-10 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
GB0004003D0 (en) * 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
CN100518827C (en) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 Controlled release hydrocodone formulations
JP2008513430A (en) * 2004-09-17 2008-05-01 ニューロキュア リミテッド Pindolol for the treatment of premenstrual syndrome and premenstrual dysphoric disorder
CN100469356C (en) * 2006-09-08 2009-03-18 山东益康药业有限公司 Slowly released tablet of compound atenolol, and preparation method

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2732335C2 (en) * 1976-07-27 1983-01-20 Sandoz-Patent-GmbH, 7850 Lörrach Tablet for the enteral administration of indolyloxyalkanolamine derivatives
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of a drug by a serotonin 1A receptor antagonist
WO1997006792A1 (en) * 1995-08-16 1997-02-27 Eli Lilly And Company Potentiation of serotonin response
EP0792649A1 (en) * 1996-02-29 1997-09-03 Eli Lilly And Company Treatment of sleep disorders

Also Published As

Publication number Publication date
HUP0003074A3 (en) 2001-12-28
SK72000A3 (en) 2000-12-11
PL338017A1 (en) 2000-09-25
ZA986138B (en) 2000-01-10
BR9810996A (en) 2000-08-08
HUP0003074A2 (en) 2001-01-29
GB9714675D0 (en) 1997-09-17
AP2000001728A0 (en) 2000-03-31
CA2295822A1 (en) 1999-01-21
OA11276A (en) 2003-07-31
WO1999002142A2 (en) 1999-01-21
KR20010021644A (en) 2001-03-15
WO1999002142A3 (en) 1999-04-15
AU9340198A (en) 1999-02-08
PE99699A1 (en) 1999-12-21
ID24191A (en) 2000-07-13
IL133869A0 (en) 2001-04-30
NO20000107L (en) 2000-01-10
MA24604A1 (en) 1999-04-01
EP0996466A2 (en) 2000-05-03
EA200000112A1 (en) 2000-10-30
CN1262627A (en) 2000-08-09
CO4950552A1 (en) 2000-09-01
DZ2556A1 (en) 2003-02-15
JP2002508003A (en) 2002-03-12
NO20000107D0 (en) 2000-01-10
TR200000074T2 (en) 2000-05-22
AR016128A1 (en) 2001-06-20

Similar Documents

Publication Publication Date Title
CZ20011427A3 (en) Pharmaceutical composition with controlled release and containing CGMP DPE-5 inhibitor
BG101139A (en) Heteroatoms-containing cyclopentanopyridyloxazolidinons
GB2365772A (en) Factor
ZA987537B (en) Stanol ester composition and production thereof.
HUP9901779A3 (en) Modified release multiple-units dosage composition
LU91758I9 (en)
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
IL122447A0 (en) Pharmaceutical composition with anaestheric effect
YU15299A (en) Pharmaceutical compositions
IL147803A0 (en) 28-epirapalogs
AU3067399A (en) Oxygen-scavenging compositions and articles
HUP0003217A3 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and pharmaceutical compositions containing them
ZA9710593B (en) Antisebum and antioxidant compositions containing gugulipid and fractions thereof.
HU9400952D0 (en) Heteroaryl-amines as acetyl-cholinesterase inhibitors
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
BG102259A (en) Compostions with controlled paroxetine release
HUP0000733A3 (en) Aminoguanidines and alkoxyguanidines as and pharmaceutical compositions containing them
AP2000002010A0 (en) Novel pharmaceutical compositions for treating and saving and the methods for the preparation thereof
PL347357A1 (en) Novel composition and use
HUP9900071A3 (en) Tribenzimidazoles useful as topoisomerase i inhibitors, pharmaceutical compositions containing them and their use
BG104119A (en) A new composition
AU749278C (en) Composition for use in dementia
UA48245C2 (en) SUBSTITUTED-2-AMINO-1,2,3,4-TETRAHYDRODIBENZOFURANS AND 2-AMINOCYCLOHEPTA[b]BENZOFURANS USEFUL AS 5-HT1F AGONISTS IN MAMMALS, PHARMACEUTICAL FORMULATION
MD970269A (en) Clavulanates
ZA949874B (en) B3-adrenergic agents, benzodioxole dicarboxylates and their use in pharmaceutical compositions.